ライフサイエンスコーパス: beneficiary

1 on Category risk score among fee-for-service beneficiaries).

2 operating prior to 2014, representing 78% of beneficiaries).

3 0 to 74 years and a smaller benefit in older beneficiaries.

4 cancer care and significant cost sharing by beneficiaries.

5 6 112 450 Medicare beneficiaries.

6 d Alzheimer disease incidence among Medicare beneficiaries.

7 ll Cardiac ICU services received by Medicare beneficiaries.

8 fectiveness of CAS versus CEA among Medicare beneficiaries.

9 ]-28 per 1000 [Utah]), averaging 19 per 1000 beneficiaries.

10 icancer therapies, particularly for Medicare beneficiaries.

11 s. 58.4+/-9.4 years for the remainder of the beneficiaries.

12 0 to 74 years and a smaller benefit in older beneficiaries.

13 itiation of digoxin or diuretics by Medicare beneficiaries.

14 REGARDS study and the 5% sample of Medicare beneficiaries.

15 italization with an infection among Medicare beneficiaries.

16 137102 hospitalizations of 20351161 Medicare beneficiaries.

17 s to increase price competition for Medicare beneficiaries.

18 ablishing a communication strategy vis a vis beneficiaries.

19 infarction (AMI) are calculated for Medicare beneficiaries.

20 ed macular degeneration (AMD) among Medicare beneficiaries.

21 ntrated among a subset of high-cost Medicare beneficiaries.

22 istinct subpopulations of high-cost Medicare beneficiaries.

23 Among 1618059 beneficiaries, 15586 patients (1.0%) had cirrhosis (mean

24 1 355 692 Medicare beneficiaries (2004 to 2012) aged 70 to 79 years at aver

25 Participants: 1 355 692 Medicare beneficiaries (2004 to 2012) aged 70 to 79 years at aver

26 iod from 162 per 1000 (2004) to 172 per 1000 beneficiaries (2013) (Ptrend <0.001 for both).

27 nistrative data for fee-for-service disabled beneficiaries 21 to 64 years of age who were alive throu

28 In a cohort of 18.9 million Medicare beneficiaries (4.2 million deaths) living across the con

29 ngitudinal cohort study was conducted of all beneficiaries 40 years or older who were continuously en

30 Results Among 3,038 beneficiaries, 41% received first-line IMiDs.

31 Among 899 physician practices with 5189880 beneficiaries, 547 practices were categorized as low ris

32 Our sample size included 5073 beneficiaries: 55% were female, 45% were >/=85 years of

33 e constructed an open cohort of all Medicare beneficiaries (60,925,443 persons) in the continental Un

34 dical and surgical conditions among Medicare beneficiaries 65 years and older.

35 Medicare beneficiaries 65 years old or older admitted for five me

36 Participants were 72,587 Medicare beneficiaries 65 years or older with (n = 4441) and with

37 Among all Medicare beneficiaries 65 years or older, a diagnosis code for FE

38 ecember 31, 2013, were measured for Medicare beneficiaries 65 years or older.

39 t 6 months and 2 years after discharge among beneficiaries 66 to 75 years of age, 17633 (58.9%) and 1

40 f mortality and hospitalization for Medicare beneficiaries 66 years old and older who have major surg

41 opioids or overdose among disabled Medicare beneficiaries, a population particularly at risk.

42 g more than $370 million to about 16 million beneficiaries across 280 temporary payment sites.

43 l retrospective review of 1,631,904 Medicare beneficiary admissions to critical access hospitals (n =

44 edicaid beneficiaries, with a mean of 606039 beneficiaries affected by plan exits annually.

45 ersistence after reinitiation among Medicare beneficiaries after hospital discharge for a myocardial

46 assessed the incidence of AKI among Medicare beneficiaries after PCI from 2004 to 2009 and subsequent

47 procedure codes, and other information about beneficiaries age 67 years or older in the Medicare clai

48 to 47%) probability of receiving IMiDs among beneficiaries age 75 to 84 years and a significantly low

49 We identified Medicare beneficiaries aged >/=65 years who received high-dose or

50 d data from German National Health Insurance beneficiaries aged 40 years or younger (n = 655,815) fro

51 rom a population of Medicare fee-for-service beneficiaries aged 65 years and older.

52 ctional analysis of Medicare fee-for-service beneficiaries aged 65 years or older from 1999 to 2014 u

53 ysis involving male Medicare fee-for-service beneficiaries aged 65 years or older hospitalized betwee

54 rospective study of Medicare fee-for-service beneficiaries aged 65 years or older hospitalized with H

55 Medicare beneficiaries aged 66 to 75 years (n = 29932) and older

56 ve had a modest benefit in preventing CRC in beneficiaries aged 70 to 74 years and a smaller benefit

57 ve had a modest benefit in preventing CRC in beneficiaries aged 70 to 74 years and a smaller benefit

58 Results: In beneficiaries aged 70 to 74 years, the 8-year risk for C

59 In beneficiaries aged 70 to 74 years, the 8-year risk for C

60 med a retrospective cohort study of Medicare beneficiaries (aged > 64 yr) admitted to 2,757 acute-car

61 -term survival among the 13 million Medicare beneficiaries (aged 65+) in this region during 2000-2013

62 cohort analysis of claims data for Medicaid beneficiaries, aged 18 to 64 years, with incident diagno

63 performed a cohort study of 469,574 Medicare beneficiaries ages >/=50 years old who received dialysis

64 This retrospective cohort study included beneficiaries ages >/=65 years during January 2007 throu

65 y 5.8% (95% CI, 4.3% to 6.9%) among Medicare beneficiaries and 4.1% (95% CI, 2.3% to 5.4%) among pati

66 esting has recently decreased among Medicare beneficiaries and in a large integrated health system.

67 aluated changes in coverage among cohorts of beneficiaries and not from longitudinal follow-up of pat

68 U.S. fee-for-service Medicare beneficiaries and Oklahoma ophthalmologist and optometri

69 In this observational cohort study, beneficiaries and their physicians were analyzed using 2

70 the US Medicare Part B Fee-for-Service (FFS) beneficiaries and their providers.

71 23251 patients in Michigan who were Medicare beneficiaries and who underwent joint replacement during

72 ravel distances and travel times between the beneficiary and the laser provider were calculated by us

73 ed for year of entry into the ACO, number of beneficiaries, and geographic region.

74 In 2010, median beneficiary annual out-of-pocket costs for a typical tre

75 Nearly half of Medicare beneficiaries are discharged to a nonhome destination af

76 ient experience for Medicare fee-for-service beneficiaries attributed to initiative practices and a g

77 ontracts to 2014 with concurrent changes for beneficiaries attributed to local non-ACO providers (con

78 Among eligible beneficiaries (average age 77 years), the primary analys

79 We studied all Medicare fee-for-service beneficiaries between 1999 and 2013, and we evaluated ra

80 up), with adjustment for geographic area and beneficiary characteristics.

81 nationally representative sample of Medicare beneficiaries, cirrhosis was associated with an increase

82 able logistic regression models adjusted for beneficiary clinical and demographic characteristics and

83 A random 20% sample of Medicare beneficiaries contributing 4482168 to 10849224 beneficia

84 critical care medicine services by Medicare beneficiaries decreased by 17.3% (37.9-31.4%), whereas t

85 Variables analyzed included aggregate beneficiary demographics, Medicare payments to ophthalmo

86 rk was to estimate and describe the Medicare beneficiaries diagnosed with hepatitis C virus (HCV) in

87 ing SEER-Medicare data, we identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011.

88 in average monthly Medicare expenditures per beneficiary did not differ significantly between initiat

89 s enrolled in hospice was 15, and 39% of the beneficiaries died within 7 days of enrollment.

90 dial infarction hospital discharge, 15.4% of beneficiaries discontinued statins.

91 During the study period, 11% of the beneficiaries disenrolled from hospice at least once.

92 Beneficiary driving distances and times to his or her YA

93 Medicaid beneficiaries enrolled in exiting plans had access to co

94 HODS AND Elderly (aged >/=66 years) Medicare beneficiaries enrolled in Medicare Part D benefit plan f

95 45 glaucoma prescriptions, and 2519 Medicare beneficiaries filled at least 1 glaucoma prescription du

96 In 2012 alone, 47% of beneficiaries filled opioid prescriptions (25% in one to

97 006, and June 30, 2009, to determine whether beneficiaries first received ranibizumab or bevacizumab

98 d endarterectomy and stenting among Medicare beneficiaries from 1999 to 2014.

99 e cohort of Taiwan National Health Insurance beneficiaries from 2000 to 2013.

100 HODS AND In a national 5% sample of Medicare beneficiaries from 2002 to 2013, we identified a cohort

101 pharmacy claims of a 20% sample of Medicare beneficiaries from 2006 to 2013 and compared rates of Al

102 ervices among fee-for-service (FFS) Medicare beneficiaries from 2012 to 2015; 2008 claims were acquir

103 es comparisons of changes for ACO-attributed beneficiaries from before the start of ACO contracts to

104 rnative to our main analysis, which excluded beneficiaries from nonexudative AMD group who received a

105 er hospital discharge among Medicare elderly beneficiaries from October 2007 through May 2015.

106 We identified 12,420 Medicare beneficiaries from the National Cardiovascular Data Regi

107 e of NO, endothelial cells, to the potential beneficiary from the lactate, neurons-prompts new questi

108 The authors identified 90,869 Medicare beneficiaries >/=65 years of age who had prescriptions f

109 cohort study of all Medicare fee-for-service beneficiaries >/=65 years of age with principal discharg

110 of 2 331 939 unique fee-for-service Medicare beneficiaries >/=65-years-old followed for all inpatient

111 infarction or cardiac arrest among Medicare beneficiaries (>/=65 years of age) in 11 U.S. cities tha

112 Beneficiaries had Medicare fee-for-service coverage incl

113 However, 25% of Medicare beneficiaries have surgery in their last 3 months of lif

114 and methods using data on N=49 763 Medicare beneficiaries hospitalized between 2011 and 2013 with a

115 A random sample of Medicare fee-for-service beneficiaries hospitalized during 2009-2014 was used to

116 Cardiovascular Project, a study of Medicare beneficiaries hospitalized for AMI, with 17 years of fol

117 Among Medicare fee-for-service beneficiaries hospitalized for heart failure, acute myoc

118 ctively; P=0.71); the characteristics of the beneficiaries hospitalized on marathon and nonmarathon d

119 erly (age, > 64 yr) fee-for-service Medicare beneficiaries hospitalized with an intensive care or cor

120 Among Medicare beneficiaries hospitalized with pneumonia who received m

121 A total of 97% of the targeted 1871 beneficiaries in 2 pilot sites were successfully paid th

122 f 1 811 094 German National Health Insurance beneficiaries in 2005 was followed until 2011.

123 ractices caring for fee-for-service Medicare beneficiaries in 2013.

124 s (2002-2006), including 28 million Medicare beneficiaries in 708 counties.

125 act surgery claims among FFS Medicare Part B beneficiaries in all 50 states and the District of Colum

126 and anti-VEGF drug claims among FFS Medicare beneficiaries in all 50 states and the District of Colum

127 community, and the NHATS comprised Medicare beneficiaries in the contiguous United States.

128 dinal observational study of 72,587 Medicare beneficiaries in the general community using the Medicar

129 Beneficiaries in the highest 10% of total standardized i

130 Among the 68374904 unique Medicare beneficiaries in the study, there were 469582 hospitaliz

131 Results: The mean age for Medicare beneficiaries in this study ranged from 74.1 years (pulm

132 total adjusted annual spending was -$144 per beneficiary in the 2012 ACO cohort as compared with the

133 istent with a 1.4% savings, but only -$3 per beneficiary in the 2013 ACO cohort as compared with the

134 data from 18166 community-dwelling Medicare beneficiaries, including 1409 individuals who were diagn

135 ut median Medicare inpatient expenditure per beneficiary increased from $2932 (interquartile range $2

136 3.7% of their household income; 10% of these beneficiaries incurred OOP expenditures that were 63.1%

137 Overall, 272, 1508, and 3113 Medicare beneficiaries initiated, added a new class of antihypert

138 Beneficiaries initiating diuretics and beneficiaries initiating digoxin were more likely to hav

139 Beneficiaries initiating diuretics and beneficiaries ini

140 In Medicare beneficiaries initiating diuretics or digoxin, this stud

141 Beneficiaries initiating diuretics were less likely to h

142 Beneficiaries initiating diuretics with laboratory value

143 pitalizations among Medicare fee-for-service beneficiaries, IVCF placement increased as utilization r

144 ted a retrospective cohort study of Medicare beneficiaries linked to laboratory data in 10 states wit

145 Among hospitalizations for US Medicare beneficiaries, major teaching hospital status was associ

146 A total of 333 ACOs with 5 329 831 Medicare beneficiaries (mean size, 16 006 beneficiaries) particip

147 ere high medical and social risk (mean, 1858 beneficiaries; mean, 269 clinicians).

148 , 102 were high social risk only (mean, 1635 beneficiaries; mean, 284 clinicians), and 122 were high

149 gh social nor high medical risk) (mean, 7909 beneficiaries; mean, 320 clinicians), 128 were high medi

150 128 were high medical risk only (mean, 3675 beneficiaries; mean, 370 clinicians), 102 were high soci

151 a sample of Taiwan National Health Insurance beneficiaries (n = 1,000,000), followed up longitudinall

152 Medicare claims data, we evaluated Medicare beneficiaries (N = 195 812) with an index claim for neov

153 w-up period were identified in exudative AMD beneficiaries newly diagnosed in 2006, the beginning of

154 dative AMD in 2006 were the treatment group; beneficiaries newly diagnosed with exudative AMD in 2000

155 this group of individuals reincluded (11% of beneficiaries newly diagnosed with nonexudative AMD in 2

156 onic conditions for Medicare fee-for-service beneficiaries' newly prescribed medications.

157 All participants were beneficiaries of a nursing quality improvement campaign

158 ears), opioid-naive trauma patients who were beneficiaries of Military Health Insurance (military per

159 t were randomly selected from all registered beneficiaries of the National Health Insurance program i

160 ng cyanobacteria and denitrifiers may be net beneficiaries of these changes, while others such as cal

161 ospective cross-sectional study of 1 050 815 beneficiaries older than 40 years of age with cataracts

162 ive cohort study of Medicare fee-for-service beneficiaries older than 64 years discharged between Jan

163 for a random 5% sample of 1 618 059 Medicare beneficiaries older than 66 years.

164 Results were similar among beneficiaries older than 75 years of age.

165 sed risk of exfoliation syndrome in Medicare beneficiaries (OR, 1.56; 95% CI, 1.42-1.72) in substudy

166 = .078), year of entry (P = .902), number of beneficiaries (P = .814), or total composite quality sco

167 31 Medicare beneficiaries (mean size, 16 006 beneficiaries) participated in the MSSP.

168 , we conducted a cohort study using Medicare beneficiaries participating in the 2001-2002 and 2003-20

169 l changes in intended management in Medicare beneficiaries participating in the National Oncologic PE

170 rapies is hindered by ignorance of potential beneficiary patient subgroups.

171 999 and 2013, among Medicare fee-for-service beneficiaries, patients were hospitalized more frequentl

172 to a relative increase of 83 visits per 1000 beneficiaries per year at demonstration sites (P<0.001).

173 rgency department visits (30.3 more per 1000 beneficiaries per year, P<0.001), inpatient admissions (

174 01), inpatient admissions (5.7 more per 1000 beneficiaries per year, P=0.02), and Medicare Part B exp

175 d Medicare Part B expenditures ($37 more per beneficiary per year, P=0.02).

176 ns, overall more than 90% of the US Medicare beneficiary population lives within a 30-minute drive of

177 d beneficiaries were matched to unvaccinated beneficiaries (primary analysis) and to HZV-unvaccinated

178 To quantify Medicare beneficiary proximity to his or her yttrium-aluminum-gar

179 ent experience, reflecting the proportion of beneficiaries rating experiences as 8 or above on a 0-to

180 020 for drug spending above $2,960 until the beneficiary reaches $4,700 in out-of-pocket spending.

181 More than 20% of Medicare beneficiaries receiving cardiac resynchronization therap

182 The rate of FFS Medicare beneficiaries receiving intravitreal injections and the

183 In 2013, the rate of FFS Medicare beneficiaries receiving intravitreal injections varied w

184 Beneficiaries residing in urban areas (aOR vs isolated r

185 .7% among poor, near-poor, and higher-income beneficiaries, respectively.

186 to after the start of the contracts between beneficiaries served by the 220 ACOs entering the MSSP i

187 general community using the Medicare Current Beneficiary Survey (2004-2009).

188 general community using the Medicare Current Beneficiary Survey (pooled 2004, 2005, 2007, and 2008 da

189 ome recognition and used Medicare claims and beneficiary surveys to measure utilization of services,

190 Out-of-pocket costs for Medicare beneficiaries taking orally administered anticancer medi

191 The overall proportion of beneficiaries that first received ranibizumab for neovas

192 For Medicare beneficiaries, the Affordable Care Act will close the Pa

193 h screening is covered for eligible Medicare beneficiaries, the generalizability of the NLST in the e

194 Among fee-for-service Medicare beneficiaries, the performance of carotid endarterectomy

195 For Medicare beneficiaries, there was no difference in geographic acc

196 omy among a large group of managed care plan beneficiaries throughout the United States.

197 anel-negative binomial models on a subset of beneficiaries to compare their acute medical service uti

198 Among hospitalized Medicare beneficiaries treated by a general internist, there were

199 nd costs of care among hospitalized Medicare beneficiaries treated by locum tenens vs non-locum tenen

200 We identified 1,945,802 Medicare beneficiaries undergoing 1 of six high-risk general or v

201 ed a retrospective review of 38,374 Medicare beneficiaries undergoing bariatric surgery between 2011

202 s a cross-sectional cohort study of Medicare beneficiaries undergoing colectomy (189229 patients at 1

203 Among Medicare beneficiaries undergoing common surgical procedures, pat

204 Among Medicare beneficiaries undergoing gastric band surgery, device-re

205 lation-based study was conducted of Medicare beneficiaries undergoing laparoscopic or open colectomy

206 Medicare beneficiaries undergoing LTP by optometrists had a 189%

207 ed by a representative sample of US Medicare beneficiaries using self-reported visual function, reinf

208 herapy for neovascular AMD among US Medicare beneficiaries varied substantially across geographic and

209 s and optometrists among FFS Medicare Part B beneficiaries was 10.9% (range by state, 0%-75%) in 2012

210 halmologists and optometrists among Medicare beneficiaries was 10.9% in 2012 and 11.1% in 2013.

211 ited States Medicaid claims among 69 million beneficiaries, we conducted a set of bidirectional self-

212 f data from Taiwan National Health Insurance beneficiaries, we found that use of PPIs in patients wit

213 e claims from a 5% random sample of Medicare beneficiaries, we identified a cohort of Medicare patien

214 r we controlled for year of treatment, black beneficiaries were 45% less likely to receive ranibizuma

215 RW beneficiaries were classified by receipt of >/=1 service

216 Outcomes after CAS and CEA among Medicare beneficiaries were comparable after adjusting for both p

217 A total of 639943 Medicare beneficiaries were included in the study.

218 HZV-vaccinated beneficiaries were matched to unvaccinated beneficiaries

219 Approximately half of the beneficiaries were women and fourth-fifths were white.

220 nction [TPJ]) encoded trial-wise empathy for beneficiaries, whereas the TPJ (but not AI) predicted th

221 We studied 105,329 Medicare beneficiaries who began a moderate- or high-intensity st

222 Of the 1.2 million fee-for-service Medicare beneficiaries who developed prostate cancer in 2001 to 2

223 community-dwelling Medicare fee-for-service beneficiaries who died between 1998 and 2012.

224 ticipants were noninstitutionalized Medicare beneficiaries who filled at least 1 glaucoma prescriptio

225 a retrospective analysis involving Medicare beneficiaries who had an index emergency department visi

226 8% (95% CI, 1.26%-1.50%) of African American beneficiaries who had an ophthalmologist eye examination

227 age or not, and with a 5% sample of Medicare beneficiaries who had FFS coverage in 2005, overall, by

228 covariates and in an analysis that included beneficiaries who had five or more chronic medical condi

229 tension initiating diuretic in 2011 and 8683 beneficiaries who had heart failure or atrial fibrillati

230 trospective cohorts from 10 states of 99 711 beneficiaries who had heart failure or hypertension init

231 s (primary analysis) and to HZV-unvaccinated beneficiaries who had received pneumococcal vaccination

232 affordability of high-cost cancer drugs for beneficiaries who need them.

233 Among beneficiaries who obtained medical care for FECD, kerato

234 -pocket costs for qualifying Medicare Part D beneficiaries who receive orally administered chemothera

235 as no difference in driving distance between beneficiaries who received a laser capsulotomy from an o

236 unty addresses of the corresponding Medicare beneficiaries who received the laser capsulotomy.

237 We used national Medicare data to identify beneficiaries who underwent 1 of 19 major surgical proce

238 Among Medicare beneficiaries who underwent CABG between 2008 and 2011,

239 al study of 116,977 Medicare fee-for-service beneficiaries who underwent colorectal surgery using adm

240 We evaluated Medicare beneficiaries who underwent emergent colectomy between 2

241 A retrospective review 5,122,240 Medicare beneficiaries who underwent future targeted procedures (

242 This retrospective review of 25042 Medicare beneficiaries who underwent gastric band placement betwe

243 in a case-crossover study of 90 127 Medicare beneficiaries who were >/=65 years old and had a serious

244 Medicare beneficiaries who were admitted to marathon-affected hos

245 Cardiovascular Project, a study of Medicare beneficiaries who were hospitalized for acute myocardial

246 tes longer) and higher 30-day mortality than beneficiaries who were hospitalized on nonmarathon dates

247 2012 and compared 30-day mortality among the beneficiaries who were hospitalized on the date of a mar

248 The percentage of beneficiaries whose first statin prescriptions filled fo

249 main stable, after the doughnut hole closes, beneficiaries will spend approximately $2,550 less.

250 Beneficiaries with a first diagnosis of exudative AMD in

251 Risks of these outcomes in beneficiaries with a history of intravitreal injections

252 tcomes after receipt of cataract surgery for beneficiaries with a history of intravitreal injections.

253 Beneficiaries with a new cancer diagnosis and Medicare a

254 For example, the percentage of beneficiaries with a prescription yielding a daily MED o

255 METHODS AND Medicare beneficiaries with a statin fill claim within 30 days af

256 Home health care Medicare beneficiaries with advanced HF who enrolled in hospice h

257 ignificant differential changes in PDC among beneficiaries with at least 1 prescription fill, except

258 t-of-pocket (OOP) costs incurred by Medicare beneficiaries with cancer and identify which factors and

259 Medicare beneficiaries with cancer are at risk for financial hard

260 Among the 10% of beneficiaries with cancer who incurred the highest OOP c

261 Participants were Medicare beneficiaries with cancer who received care at participa

262 a national cohort of United States Medicare beneficiaries with cataract, cataract surgery was associ

263 sine kinase inhibitors (TKIs) among Medicare beneficiaries with chronic myeloid leukemia (CML) with a

264 Conclusion Only 68% of Medicare beneficiaries with CML initiated TKI therapy within 6 mo

265 ms with high and low teamwork levels treated beneficiaries with comparable comorbidity scores, these

266 grams), we examined the annual prevalence of beneficiaries with four or more opioid prescribers, pres

267 Medicare beneficiaries with glaucoma had higher adjusted odds of

268 In the risk-adjusted model, Medicare beneficiaries with glaucoma incurred an additional $2903

269 Medicare Part D enrolled most beneficiaries with glaucoma who previously lacked prescr

270 We performed an analysis of Medicare beneficiaries with HCC diagnoses from 2007 to 2009.

271 Of 10 443 Medicare beneficiaries with heart failure started on an MRA, 19.7

272 Compared to beneficiaries with high statin adherence, statin intoler

273 ntial increase in the use of thiazides among beneficiaries with hypertension in the 2013 entry cohort

274 We examined a national cohort of Medicare beneficiaries with incident stage I to III HER2-positive

275 Conclusion Medicare beneficiaries with myeloma who do not receive LISs face

276 (IMiDs; lenalidomide and thalidomide) among beneficiaries with myeloma, who can receive either orall

277 dicare Part D, which was designed to provide beneficiaries with near-universal prescription drug cove

278 propensity-score matched cohorts of Medicare beneficiaries with PAD from 2006 through 2009.

279 propensity-score matched cohorts of Medicare beneficiaries with PAD from 2006 through 2009.

280 Among 65,747 Medicare beneficiaries with pneumonia who required mechanical ven

281 events, and all-cause mortality in Medicare beneficiaries with statin intolerance and in those with

282 ariate-adjusted hazard ratios (HR) comparing beneficiaries with statin intolerance versus those with

283 nd compared the effect on Medicare Parts A/B beneficiaries with the effect on patients with other typ

284 hanges in the epidemiology of HF in Medicare beneficiaries, with a decline in incident HF and a decre

285 hese exiting plans enrolled 4848310 Medicaid beneficiaries, with a mean of 606039 beneficiaries affec

286 riptive analysis of Medicare fee-for-service beneficiaries, with at least one home health claim betwe

287 ere one-shot donations are made to unrelated beneficiaries without any guarantee of payback.

288 ross all economic strata, with reductions in beneficiaries without coverage from 22.8% to 4.0%, 29.1%

289 1.13-1.43; P < .001) compared with Medicare beneficiaries without glaucoma.

290 onoutpatient services compared with Medicare beneficiaries without glaucoma.

291 s, and the estimated out-of-pocket costs for beneficiaries without low-income subsidies who take a si

292 Medicare beneficiaries without supplemental insurance incur signi

293 prescription drug coverage among vulnerable beneficiaries would likely improve access to prescribed

294 ting and the rate decreased to 38 per 100000 beneficiary-years (P < .001).

295 nd 2010, rates of IVCF placement per 100,000 beneficiary-years and per 1,000 patients with PE were de

296 and 36325 in 2014; national rates per 100000 beneficiary-years decreased from 298 in 1999-2000 to 128

297 neficiaries contributing 4482168 to 10849224 beneficiary-years for analysis from 2009 to 2014, depend

298 esenting an increase in the rate per 100,000 beneficiary-years from 19.0 to 32.5 (p < 0.001 for both)

299 999 to 22865 in 2006 (an increase per 100000 beneficiary-years from 40 in 1999-2000 to 75 in 2005-200

300 Revascularization rates per 100000 beneficiary-years of fee-for-service enrollment, in-hosp